Crescendo Pharmaceuticals Corp.

The launch of monoclonal antibody (MAb) immune checkpoint inhibitors (ICIs) in the past decade has been game changing and provided new treatment options across the spectrum of solid tumor types and he

With the approval of its first product for a client and subsequent boost to its credibility and valuation, the biotech drug delivery firm is angling to own bigger pieces of the drugs it helps to creat

A few changes in accounting rules further beleaguer medical start-ups and rock large company growth plans. by Roger Longman In early December, 1998, Alkermes Inc. , the Cambridge, MA-based drug del

In the following interviews, experts from the pharmaceutical, medical device and diagnostics industries, as well as two fund managers focused on small-cap stocks, look back on this past year's trials